Vanda Pharmaceuticals | VNDA - Operating Profit


Vanda Pharmaceuticals reported $-40.66M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.94B 239M Mar/2026
Takeda JPY -13.62B 182.44B Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Veracyte USD 19.08M 5.55M Mar/2026